Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
This article was originally published in The Pink Sheet
Executive Summary
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.